about
The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancerWhen genome integrity and cell cycle decisions collide: roles of polo kinases in cellular adaptation to DNA damage.Methylseleninic acid enhances the effect of etoposide to inhibit prostate cancer growth in vivo.Inhibition of telomerase activity preferentially targets aldehyde dehydrogenase-positive cancer stem-like cells in lung cancer.Multiscale in situ analysis of the role of dyskerin in lung cancer cells.VEGF elicits epithelial-mesenchymal transition (EMT) in prostate intraepithelial neoplasia (PIN)-like cells via an autocrine loop.Checkpoint adaptation: Keeping Cdc5 in the T-loop.Centrosome-Dependent Bypass of the DNA Damage Checkpoint by the Polo Kinase Cdc5.
P50
Q28388047-E67693FF-DAA8-47B1-8F55-964BD87683F5Q38241194-9998DE16-3787-49B6-B124-D078AA1F1F4FQ38301472-65A97421-7A78-4567-AD59-2587F802E9F8Q38801841-44872414-E0A4-4969-8CF8-93A9F38AD4C1Q39227538-7340BD77-611E-42C3-9AE0-315B8A7A336DQ39763987-7B685975-F491-41F8-95E9-5C54A4D52FA5Q41664305-D5D31845-D169-4373-A0C1-6DEAF40B6637Q52886508-054EDDCB-65CF-4179-9099-EC230257B773
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-3729-9195
@en
name
D Serrano
@ast
D Serrano
@en
D Serrano
@nl
type
label
D Serrano
@ast
D Serrano
@en
D Serrano
@nl
prefLabel
D Serrano
@ast
D Serrano
@en
D Serrano
@nl
P106
P31
P496
0000-0002-3729-9195